newsfilter
← Latest News
GlobeNewswire·

Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™

CNSY
  • Cerenome, Inc. announced new preclinical data presented at the 16th Biennial Rivkin Ovarian Cancer Research Symposium in October 2026 regarding REYOBIQ™ (rhenium Re186 obisbemeda).
  • Findings indicate a dual mechanism of action where REYOBIQ delivers targeted beta radiation to cause tumor injury & activate DNA-damage, p53, & apoptosis programs within 24 hours.
  • The treatment converts immunologically resistant "cold" tumors into immunologically responsive "hot" tumors by increasing interferon signaling & antigen presentation while decreasing IL-10 & macrophage-driven immunosuppression.
  • Combination therapy with anti-PD-1 checkpoint blockade in two mouse models of aggressive epithelial ovarian cancer resulted in improved antitumor activity & extended median survival to 65 days.
  • Single-cell RNA sequencing confirmed that immune cell recruitment, including CD8+ cytotoxic T cells & natural killer cells, peaked at 24 hours & persisted through Day 28 in combination models.
  • Dose-dependent antitumor activity was observed in the ID8agg model, with the highest dose (1.257 mCi) showing the deepest & longest-lasting tumor suppression.
  • The combination of 186RNL & anti-PD-1 reduced tumor burden with no evidence of substantial added toxicity or prolonged weight loss compared to either agent alone.
  • REYOBIQ is an investigational radiotherapeutic designed to deliver high-dose radiation locally while minimizing exposure to the rest of the body, currently being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, & pediatric brain cancers.
  • The data was presented by researchers from The University of Texas Health Science Center at San Antonio, who tracked immune changes in both tumor tissue & ascites fluid.
  • Cerenome is characterizing REYOBIQ's immunomodulatory activity across a range of tumors to support future combination strategies with immune checkpoint inhibitors.